Harnessing the immunomodulatory effects of exercise to enhance the efficacy of monoclonal antibody therapies against B-cell haematological cancers: a narrative review

Frontiers in Oncology

Oncology

John P. Campbell¹  Adam J. Causer¹  Harrison D. Collier-Bain¹  Annabelle Emery¹  Rebecca Oliver²  Frankie F. Brown³  James E. Turner⁴  Sally Moore⁵  James Murray⁵ 

[1] Department for Health, University of Bath, Bath, United Kingdom;Department for Health, University of Bath, Bath, United Kingdom;Department of Haematology, Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom;Department for Health, University of Bath, Bath, United Kingdom;School of Applied Sciences, Edinburgh Napier University, Edinburgh, United Kingdom;Department for Health, University of Bath, Bath, United Kingdom;School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom;Department of Haematology, Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom;

关键词: exercise;    cancer therapy;    natural killer cells;    phagocytes;    complement proteins;    T-cells;    B-cells;   

DOI  :  10.3389/fonc.2023.1244090

 received in 2023-06-21, accepted in 2023-08-09,  发布年份 2023

来源: Frontiers

【 摘 要 】

Therapeutic monoclonal antibodies (mAbs) are standard care for many B-cell haematological cancers. The modes of action for these mAbs include: induction of cancer cell lysis by activating Fcγ-receptors on innate immune cells; opsonising target cells for antibody-dependent cellular cytotoxicity or phagocytosis, and/or triggering the classical complement pathway; the simultaneous binding of cancer cells with T-cells to create an immune synapse and activate perforin-mediated T-cell cytotoxicity against cancer cells; blockade of immune checkpoints to facilitate T-cell cytotoxicity against immunogenic cancer cell clones; and direct delivery of cytotoxic agents via internalisation of mAbs by target cells. While treatment regimens comprising mAb therapy can lead to durable anti-cancer responses, disease relapse is common due to failure of mAb therapy to eradicate minimal residual disease. Factors that limit mAb efficacy include: suboptimal effector cell frequencies, overt immune exhaustion and/or immune anergy, and survival of diffusely spread tumour cells in different stromal niches. In this review, we discuss how immunomodulatory changes arising from exposure to structured bouts of acute exercise might improve mAb treatment efficacy by augmenting (i) antibody-dependent cellular cytotoxicity, (ii) antibody-dependent cellular phagocytosis, (iii) complement-dependent cytotoxicity, (iv) T-cell cytotoxicity, and (v) direct delivery of cytotoxic agents.

【 授权许可】

Unknown   
Copyright © 2023 Collier-Bain, Brown, Causer, Emery, Oliver, Moore, Murray, Turner and Campbell